1. Irving JA, Young RH. Microcystic stromal tumor of the ovary: report of 16 cases of a hitherto uncharacterized distinctive ovarian neoplasm. Am J Surg Pathol. 2009; 33:367–375.
2. Maeda D, Shibahara J, Sakuma T, Isobe M, Teshima S, Mori M, et al. β-catenin (CTNNB1) S33C mutation in ovarian microcystic stromal tumors. Am J Surg Pathol. 2011; 35:1429–1440.
3. Yang M, Bhattacharjee MB. Ovarian microcystic stromal tumor: report of a new entity with immunohistochemical and ultrastructural studies. Ultrastruct Pathol. 2014; 38:261–267.
4. Kang YN, Cho CH, Kwon SY. Microcystic stromal tumor of the ovary with mutation in exon 3 of β-catenin: a case report. Int J Gynecol Pathol. 2015; 34:121–125.
5. Lee SH, Koh YW, Roh HJ, Cha HJ, Kwon YS. Ovarian microcystic stromal tumor: a novel extracolonic tumor in familial adenomatous polyposis. Genes Chromosomes Cancer. 2015; 54:353–360.
6. Bi R, Bai QM, Yang F, Wu LJ, Cheng YF, Shen XX, et al. Microcystic stromal tumour of the ovary: frequent mutations of β-catenin (CTNNB1) in six cases. Histopathology. 2015; 67:872–879.
7. Reichert RA. Diagnostic gynecologic and obstetric pathology. 1st ed. Philadelphia (PA): Lippincott Williams & Wilkins;2012.
8. Morin PJ. beta-catenin signaling and cancer. Bioessays. 1999; 21:1021–1030.
9. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17:9–26.
10. Berton S, Belletti B, Wolf K, Canzonieri V, Lovat F, Vecchione A, et al. The tumor suppressor functions of p27(kip1) include control of the mesenchymal/amoeboid transition. Mol Cell Biol. 2009; 29:5031–5045.